ResearcherCentre National de la Recherche ScientifiqueNo recent work listed
Daniel Olive
Matched on ORCID iD 0000-0003-1299-4113; OpenAlex author ID A5029679351. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 19
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 5
- Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review. Last author DOI 10.3390/jcm11071948↗
- Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2018.1561120↗
- Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. Last author DOI 10.3389/fimmu.2018.01044↗
- BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1080/2162402x.2017.1372080↗
- Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer. Co-author DOI 10.4161/onci.1.1.18459↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Juan Iovanna · 3 shared papers, 2017–2019 · strength 0.25
- Paper Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. DOI 10.3389/fimmu.2018.01044↗
- Paper Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Jonathan Garnier · 1 shared paper, 2022 · strength 0.22
- Olivıer Turrini · 1 shared paper, 2022 · strength 0.22
- Etienne D. Foucher · 2 shared papers, 2017–2018 · strength 0.15
- Paper Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. DOI 10.3389/fimmu.2018.01044↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Salem Chouaı̈b · 2 shared papers, 2017–2018 · strength 0.15
- Paper Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. DOI 10.3389/fimmu.2018.01044↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Nelson Dusetti · 2 shared papers, 2017–2019 · strength 0.15
- Paper Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Daniele Fanale · 1 shared paper, 2019 · strength 0.09
- Benjamin Bian · 1 shared paper, 2019 · strength 0.09
- Antonio Dello Russo · 1 shared paper, 2019 · strength 0.09
- Céline Loncle · 1 shared paper, 2017 · strength 0.06
- Véronique Secq · 1 shared paper, 2017 · strength 0.06
- Elena Vila-Navarro · 1 shared paper, 2017 · strength 0.06
- Jean–Charles Dagorn · 1 shared paper, 2017 · strength 0.06
- Audrey Benyamine · 1 shared paper, 2017 · strength 0.06
- Meritxell Gironella · 1 shared paper, 2017 · strength 0.06
- Evelyne Béraud · 1 shared paper, 2012 · strength 0.04
- Aurélie Collignon · 1 shared paper, 2012 · strength 0.04
- Dominique Lombardo · 1 shared paper, 2012 · strength 0.04
- Eric Mas · 1 shared paper, 2012 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.